Vimarsana
Biggest News Aggregation in the World

Page 6 - Mark Lebwohl News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Mark Lebwohl. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Mark Lebwohl Today - Breaking & Trending Today

Topical PDE4 Inhibitor for Plaque Psoriasis Passes Muster With FDA - Vimarsana News

Topical PDE4 Inhibitor for Plaque Psoriasis Passes Muster With FDA

Roflumilast cream first topical agent that specifically improved intertriginous psoriasis

Cara Therapeutics : Announces Positive Topline Results from KOMFORT Phase 2 Trial of Oral Difelikefalin for the Treatment of Pruritus in Patients with Notalgia Paresthetica - Form 8-K - Vimarsana News

Cara Therapeutics : Announces Positive Topline Results from KOMFORT Phase 2 Trial of Oral Difelikefalin for the Treatment of Pruritus in Patients with Notalgia Paresthetica - Form 8-K

Cara Therapeutics Announces Positive Topline Results from KOMFORT Phase 2 Trial of Oral Difelikefalin for the Treatment of Pruritus in Patients with Notalgia Paresthetica -Study... | June 30, 2022

Vtama (Tapinarof) Cream for Psoriasis Gets FDA Approval - Vimarsana News

Vtama (Tapinarof) Cream for Psoriasis Gets FDA Approval

Vtama (tapinarof) is a new treatment for psoriasis that, unlike topical steroids, that can be used anywhere on the body and without time restrictions.

FDA Approves Dermavant's VTAMA (tapinarof) cream, 1% for the Treatment of Plaque Psoriasis in Adults: First Topical Novel Chemical Entity Launched for Psoriasis in the U.S. in 25 Years - Vimarsana News

FDA Approves Dermavant's VTAMA (tapinarof) cream, 1% for the Treatment of Plaque Psoriasis in Adults: First Topical Novel Chemical Entity Launched for Psoriasis in the U.S. in 25 Years

- EFFICACY: In the pivotal Phase 3 clinical trial program, VTAMA cream met all primary and secondary endpoints and demonstrated highly statistically significant improvement versus vehicle in Physician

FDA approves Roivant drug, the first novel topical plaque psoriasis med in 25 years - Vimarsana News

FDA approves Roivant drug, the first novel topical plaque psoriasis med in 25 years

Plaque psoriasis drug Vtama is now approved by the FDA, making it the first novel topical treatment for the chronic autoimmune disorder in a generation. Roivant Sciences subsidiary Dermavant Sciences acquired the drug from GlaxoSmithKline in 2018.